CDX2: Linking Cell and Patient Fates in Colon Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26849302.
- Also identified by DOI 10.1016/j.stem.2016.01.011 and PMC identifier 5497577.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Administering adjuvant chemotherapy to stage II colon cancer patients is controversial due to limited benefit observed for this subpopulation. Recently, Dalerba et al. (2016) identified a subgroup of stage II patients that might benefit from adjuvant chemotherapy based on lack of CDX2 expression in their cancer stem cells.
Medical subject headings
- Cell Lineage
- Colonic Neoplasms